FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Hikma Pharmaceuticals PLC HIK shares rallied 1.73% to £21.12 Tuesday, on what proved to be an all-around positive trading ...

In early April, President Donald Trump gathered dozens of hard-hat-clad coal miners around him in the White House East Room.

Coca-Cola's vitaminwater has taken a different approach with its rebrand. It's ditching the previous slightly pharmaceutical-looking identity in favour of bolder branding that aims to be fun rather ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Society of Clinical ...

Covington & Burling steered Germany’s first IPO of 2025 amid a wave of delistings and market caution, so is this a legal and ...

"Fresh thinking and a strong community are essential to transforming how we bring medicines to patients," says Rik Van Mol, ...

Wilson's new company, Philadelphia-based Gemma Biotherapeutics, plans to start testing gene therapies in Brazil this year.

2 M&A plays a key role in bringing highly lucrative medications to market, as large pharmaceutical companies often look to invest in young biotechnology companies for their innovative products.

Astellas Pharma Inc. is a Japanese pharmaceutical company with a global presence. It has been engaged in the business of ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...